Front Cover: Beyond the Toll-Like Receptor 4. Structure-Dependent Lipopolysaccharide Recognition Systems: How far are we? (ChemMedChem 6/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2025-03-16 DOI:10.1002/cmdc.202580601

Stefania De Chiara, Luca De Simone Carone, Roberta Cirella, Dr. Emanuela Andretta, Prof. Alba Silipo, Prof. Antonio Molinaro, Dr. Marcello Mercogliano, Prof. Flaviana Di Lorenzo

{"title":"Front Cover: Beyond the Toll-Like Receptor 4. Structure-Dependent Lipopolysaccharide Recognition Systems: How far are we? (ChemMedChem 6/2025)","authors":"Stefania De Chiara, Luca De Simone Carone, Roberta Cirella, Dr. Emanuela Andretta, Prof. Alba Silipo, Prof. Antonio Molinaro, Dr. Marcello Mercogliano, Prof. Flaviana Di Lorenzo","doi":"10.1002/cmdc.202580601","DOIUrl":null,"url":null,"abstract":"<p>Gram-negative bacteria release lipopolysaccharides (LPS) into our bodies, acting as potent modulators of inflammation. These molecules can enhance or attenuate inflammation. Beyond the largely studied MD2/TLR4, a complex set of other receptors interact with LPS producing diverse effects. Understanding how the structural features of LPS affect the activity and crosstalk among various receptors is crucial for developing new drugs to treat immune-related pathologies. This review aims to persuade researchers with interest in this field to perform their research activities by always using a structure to function approach. More details can be found in article cmdc.202400780 by Marcello Mercogliano, Flaviana Di Lorenzo, and co-workers. \n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 6","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202580601","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202580601","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Gram-negative bacteria release lipopolysaccharides (LPS) into our bodies, acting as potent modulators of inflammation. These molecules can enhance or attenuate inflammation. Beyond the largely studied MD2/TLR4, a complex set of other receptors interact with LPS producing diverse effects. Understanding how the structural features of LPS affect the activity and crosstalk among various receptors is crucial for developing new drugs to treat immune-related pathologies. This review aims to persuade researchers with interest in this field to perform their research activities by always using a structure to function approach. More details can be found in article cmdc.202400780 by Marcello Mercogliano, Flaviana Di Lorenzo, and co-workers.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

封面：超越 Toll-Like 受体 4。结构依赖性脂多糖识别系统：我们还有多远？(ChemMedChem 6/2025)

革兰氏阴性菌释放脂多糖（LPS）进入我们的身体，作为有效的炎症调节剂。这些分子可以增强或减弱炎症。除了被广泛研究的MD2/TLR4外，还有一组复杂的其他受体与LPS相互作用，产生多种作用。了解脂多糖的结构特征如何影响各种受体之间的活性和串扰，对于开发治疗免疫相关疾病的新药至关重要。本综述旨在说服对该领域感兴趣的研究人员通过始终使用结构到功能的方法来进行研究活动。更多细节可以在cmdc文章中找到。Marcello Mercogliano， Flaviana Di Lorenzo及其同事。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.